BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, da Silva Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Neriah DB, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U. Minimal PU.1 reduction induces a preleukemic state and promotes development of acute myeloid leukemia. Nat Med 2015;21:1172-81. [PMID: 26343801 DOI: 10.1038/nm.3936] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 10.9] [Reference Citation Analysis]
Number Citing Articles
1 Bašová P, Paszeková H, Minařík L, Dluhošová M, Burda P, Stopka T. Combined Approach to Leukemic Differentiation Using Transcription Factor PU.1-Enhancing Agents. Int J Mol Sci 2022;23:6729. [PMID: 35743167 DOI: 10.3390/ijms23126729] [Reference Citation Analysis]
2 Gupta M, Will B. SEPHguarding acute myeloid leukemia. Cell Stem Cell 2022;29:350-2. [PMID: 35245465 DOI: 10.1016/j.stem.2022.02.007] [Reference Citation Analysis]
3 Chavez JS, Rabe JL, Hernandez G, Mills TS, Niño KE, Davizon-castillo P, Pietras EM. PU.1 Expression Defines Distinct Functional Activities in the Phenotypic HSC Compartment of a Murine Inflammatory Stress Model. Cells 2022;11:680. [DOI: 10.3390/cells11040680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
4 Almohsen F, Al-rubaie HA, Habib MA, Nasr SA, Perni R, Al-quraishi L. Circulating miR-126-3p and miR-423-5p Expression in de novo Adult Acute Myeloid Leukemia: Correlations with Response to Induction Therapy and the 2-Year Overall Survival. JBM 2022;Volume 13:83-92. [DOI: 10.2147/jbm.s347397] [Reference Citation Analysis]
5 Da Ros F, Persano L, Bizzotto D, Michieli M, Braghetta P, Mazzucato M, Bonaldo P. Emilin-2 is a component of bone marrow extracellular matrix regulating mesenchymal stem cell differentiation and hematopoietic progenitors. Stem Cell Res Ther 2022;13:2. [PMID: 35012633 DOI: 10.1186/s13287-021-02674-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Guo P, Farahat AA, Paul A, Boykin DW, Wilson WD. Engineered modular heterocyclic-diamidines for sequence-specific recognition of mixed AT/GC base pairs at the DNA minor groove. Chem Sci 2021;12:15849-61. [PMID: 35024109 DOI: 10.1039/d1sc04720e] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
7 Christen F, Hablesreiter R, Hoyer K, Hennch C, Maluck-Böttcher A, Segler A, Madadi A, Frick M, Bullinger L, Briest F, Damm F. Modeling clonal hematopoiesis in umbilical cord blood cells by CRISPR/Cas9. Leukemia 2021. [PMID: 34782715 DOI: 10.1038/s41375-021-01469-x] [Reference Citation Analysis]
8 Dang D, Liu Y, Zhou Q, Li H, Wang Y, Wu H. Identification of a novel IRF8 homozygous mutation causing neutrophilia, monocytopenia and fatal infection in a female neonate. Infect Genet Evol 2021;96:105121. [PMID: 34666172 DOI: 10.1016/j.meegid.2021.105121] [Reference Citation Analysis]
9 Yun H, Narayan N, Vohra S, Giotopoulos G, Mupo A, Madrigal P, Sasca D, Lara-Astiaso D, Horton SJ, Agrawal-Singh S, Meduri E, Basheer F, Marando L, Gozdecka M, Dovey OM, Castillo-Venzor A, Wang X, Gallipoli P, Müller-Tidow C, Osborne CS, Vassiliou GS, Huntly BJP. Mutational synergy during leukemia induction remodels chromatin accessibility, histone modifications and three-dimensional DNA topology to alter gene expression. Nat Genet 2021;53:1443-55. [PMID: 34556857 DOI: 10.1038/s41588-021-00925-9] [Reference Citation Analysis]
10 Gluba-Brzózka A, Franczyk B, Rysz-Górzyńska M, Rokicki R, Koziarska-Rościszewska M, Rysz J. Pathomechanisms of Immunological Disturbances in β-Thalassemia. Int J Mol Sci 2021;22:9677. [PMID: 34575839 DOI: 10.3390/ijms22189677] [Reference Citation Analysis]
11 Taylor SJ, Sundaravel S, Steidl U. Exploiting a key transcriptional dependency: ZMYND8 and IRF8 in AML. Mol Cell 2021;81:3445-6. [PMID: 34478652 DOI: 10.1016/j.molcel.2021.08.013] [Reference Citation Analysis]
12 Barabino SML, Citterio E, Ronchi AE. Transcription Factors, R-Loops and Deubiquitinating Enzymes: Emerging Targets in Myelodysplastic Syndromes and Acute Myeloid Leukemia. Cancers (Basel) 2021;13:3753. [PMID: 34359655 DOI: 10.3390/cancers13153753] [Reference Citation Analysis]
13 Stauber J, Greally JM, Steidl U. Preleukemic and leukemic evolution at the stem cell level. Blood 2021;137:1013-8. [PMID: 33275656 DOI: 10.1182/blood.2019004397] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Wheat JC, Steidl U. Gene Expression at a Single Molecule Level: Implications for MDS and AML. Blood 2021:blood. [PMID: 34157070 DOI: 10.1182/blood.2019004261] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Harama D, Yahata T, Kagami K, Abe M, Ando N, Kasai S, Tamai M, Akahane K, Inukai T, Kiyokawa N, Ibrahim AA, Ando K, Sugita K. IMiDs uniquely synergize with TKIs to upregulate apoptosis of Philadelphia chromosome-positive acute lymphoblastic leukemia cells expressing a dominant-negative IKZF1 isoform. Cell Death Discov 2021;7:139. [PMID: 34117218 DOI: 10.1038/s41420-021-00523-y] [Reference Citation Analysis]
16 O'Brien G, Cruz-Garcia L, Zyla J, Brown N, Finnon R, Polanska J, Badie C. Kras mutations and PU.1 promoter methylation are new pathways in murine radiation-induced AML. Carcinogenesis 2020;41:1104-12. [PMID: 31646336 DOI: 10.1093/carcin/bgz175] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Fiskus W, Mill CP, Nabet B, Perera D, Birdwell C, Manshouri T, Lara B, Kadia TM, DiNardo C, Takahashi K, Daver N, Bose P, Masarova L, Pemmaraju N, Kornblau S, Borthakur G, Montalban-Bravo G, Manero GG, Sharma S, Stubbs M, Su X, Green MR, Coarfa C, Verstovsek S, Khoury JD, Vakoc CR, Bhalla KN. Superior efficacy of co-targeting GFI1/KDM1A and BRD4 against AML and post-MPN secondary AML cells. Blood Cancer J 2021;11:98. [PMID: 34016956 DOI: 10.1038/s41408-021-00487-3] [Reference Citation Analysis]
18 Wahlster L, Sankaran VG. I SPI1 something needed for B cells. J Exp Med 2021;218:e20210572. [PMID: 33978700 DOI: 10.1084/jem.20210572] [Reference Citation Analysis]
19 Le Coz C, Nguyen DN, Su C, Nolan BE, Albrecht AV, Xhani S, Sun D, Demaree B, Pillarisetti P, Khanna C, Wright F, Chen PA, Yoon S, Stiegler AL, Maurer K, Garifallou JP, Rymaszewski A, Kroft SH, Olson TS, Seif AE, Wertheim G, Grant SFA, Vo LT, Puck JM, Sullivan KE, Routes JM, Zakharova V, Shcherbina A, Mukhina A, Rudy NL, Hurst ACE, Atkinson TP, Boggon TJ, Hakonarson H, Abate AR, Hajjar J, Nicholas SK, Lupski JR, Verbsky J, Chinn IK, Gonzalez MV, Wells AD, Marson A, Poon GMK, Romberg N. Constrained chromatin accessibility in PU.1-mutated agammaglobulinemia patients. J Exp Med 2021;218:e20201750. [PMID: 33951726 DOI: 10.1084/jem.20201750] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
20 Chavez JS, Rabe JL, Loeffler D, Higa KC, Hernandez G, Mills TS, Ahmed N, Gessner RL, Ke Z, Idler BM, Niño KE, Kim H, Myers JR, Stevens BM, Davizon-Castillo P, Jordan CT, Nakajima H, Ashton J, Welner RS, Schroeder T, DeGregori J, Pietras EM. PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. J Exp Med 2021;218:e20201169. [PMID: 33857288 DOI: 10.1084/jem.20201169] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
21 Schwenger E, Steidl U. An evolutionary approach to clonally complex hematologic disorders. Blood Cancer Discov 2021;2:201-15. [PMID: 34027415 DOI: 10.1158/2643-3230.bcd-20-0219] [Reference Citation Analysis]
22 Wang X, Jin P, Zhang Y, Wang K. CircSPI1 acts as an oncogene in acute myeloid leukemia through antagonizing SPI1 and interacting with microRNAs. Cell Death Dis 2021;12:297. [PMID: 33741901 DOI: 10.1038/s41419-021-03566-2] [Reference Citation Analysis]
23 Giacopelli B, Wang M, Cleary A, Wu YZ, Schultz AR, Schmutz M, Blachly JS, Eisfeld AK, Mundy-Bosse B, Vosberg S, Greif PA, Claus R, Bullinger L, Garzon R, Coombes KR, Bloomfield CD, Druker BJ, Tyner JW, Byrd JC, Oakes CC. DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia. Genome Res 2021;31:747-61. [PMID: 33707228 DOI: 10.1101/gr.269233.120] [Reference Citation Analysis]
24 Ueda K, Kumari R, Schwenger E, Wheat JC, Bohorquez O, Narayanagari SR, Taylor SJ, Carvajal LA, Pradhan K, Bartholdy B, Todorova TI, Goto H, Sun D, Chen J, Shan J, Song Y, Montagna C, Xiong S, Lozano G, Pellagatti A, Boultwood J, Verma A, Steidl U. MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism. Cancer Cell 2021;39:529-547.e7. [PMID: 33667384 DOI: 10.1016/j.ccell.2021.02.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
25 Kim MY, Yan B, Huang S, Qiu Y. Regulating the Regulators: The Role of Histone Deacetylase 1 (HDAC1) in Erythropoiesis. Int J Mol Sci 2020;21:E8460. [PMID: 33187090 DOI: 10.3390/ijms21228460] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Wu J, Krchma K, Lee HJ, Prabhakar S, Wang X, Zhao H, Xing X, Seong RH, Fremont DH, Artyomov MN, Wang T, Choi K. Requisite Chromatin Remodeling for Myeloid and Erythroid Lineage Differentiation from Erythromyeloid Progenitors. Cell Rep 2020;33:108395. [PMID: 33207205 DOI: 10.1016/j.celrep.2020.108395] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Su A, Ling F, Vaganay C, Sodaro G, Benaksas C, Dal Bello R, Forget A, Pardieu B, Lin KH, Rutter JC, Bassil CF, Fortin G, Pasanisi J, Antony-Debré I, Alexe G, Benoist JF, Pruvost A, Pikman Y, Qi J, Schlageter MH, Micol JB, Roti G, Cluzeau T, Dombret H, Preudhomme C, Fenouille N, Benajiba L, Golan HM, Stegmaier K, Lobry C, Wood KC, Itzykson R, Puissant A. The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies. Cancer Discov 2020;10:1894-911. [PMID: 32826232 DOI: 10.1158/2159-8290.CD-19-0970] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 McKenzie MD, Ghisi M, Oxley EP, Ngo S, Cimmino L, Esnault C, Liu R, Salmon JM, Bell CC, Ahmed N, Erlichster M, Witkowski MT, Liu GJ, Chopin M, Dakic A, Simankowicz E, Pomilio G, Vu T, Krsmanovic P, Su S, Tian L, Baldwin TM, Zalcenstein DA, DiRago L, Wang S, Metcalf D, Johnstone RW, Croker BA, Lancaster GI, Murphy AJ, Naik SH, Nutt SL, Pospisil V, Schroeder T, Wall M, Dawson MA, Wei AH, de Thé H, Ritchie ME, Zuber J, Dickins RA. Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell 2019;25:258-272.e9. [PMID: 31374198 DOI: 10.1016/j.stem.2019.07.001] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 13.5] [Reference Citation Analysis]
29 Bresnick EH, Johnson KD. Blood disease-causing and -suppressing transcriptional enhancers: general principles and GATA2 mechanisms. Blood Adv 2019;3:2045-56. [PMID: 31289032 DOI: 10.1182/bloodadvances.2019000378] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
30 Shin E, Jeong J, Chung H, Jung H, Park C, Yoon SR, Kim T, Lee SJ, Choi I, Noh J. The Gata1 murine megakaryocyte–erythroid progenitor cells expand robustly and alter differentiation potential. Biochemical and Biophysical Research Communications 2020;528:46-53. [DOI: 10.1016/j.bbrc.2020.04.143] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
31 Wheat JC, Sella Y, Willcockson M, Skoultchi AI, Bergman A, Singer RH, Steidl U. Single-molecule imaging of transcription dynamics in somatic stem cells. Nature 2020;583:431-6. [PMID: 32581360 DOI: 10.1038/s41586-020-2432-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
32 Srivastava P, Tzetzo SL, Gomez EC, Eng KH, Jani Sait SN, Kuechle JB, Singh PK, De Jong K, Wiatrowski KR, Peresie J, Dimitroff A, Lynch ML, Wang J, Abrams SI, Griffiths EA, Nemeth MJ. Inhibition of LSD1 in MDS progenitors restores differentiation of CD141Hi conventional dendritic cells. Leukemia 2020;34:2460-72. [PMID: 32099035 DOI: 10.1038/s41375-020-0765-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Xhani S, Lee S, Kim HM, Wang S, Esaki S, Ha VLT, Khanezarrin M, Fernandez GL, Albrecht AV, Aramini JM, Germann MW, Poon GMK. Intrinsic disorder controls two functionally distinct dimers of the master transcription factor PU.1. Sci Adv 2020;6:eaay3178. [PMID: 32128405 DOI: 10.1126/sciadv.aay3178] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
34 Vetrie D, Helgason GV, Copland M. The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nat Rev Cancer 2020;20:158-73. [PMID: 31907378 DOI: 10.1038/s41568-019-0230-9] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 25.0] [Reference Citation Analysis]
35 Mitchell K, Steidl U. Targeting Immunophenotypic Markers on Leukemic Stem Cells: How Lessons from Current Approaches and Advances in the Leukemia Stem Cell (LSC) Model Can Inform Better Strategies for Treating Acute Myeloid Leukemia (AML). Cold Spring Harb Perspect Med 2020;10:a036251. [PMID: 31451539 DOI: 10.1101/cshperspect.a036251] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
36 Luo H, Zhu G, Xu J, Lai Q, Yan B, Guo Y, Fung TK, Zeisig BB, Cui Y, Zha J, Cogle C, Wang F, Xu B, Yang FC, Li W, So CWE, Qiu Y, Xu M, Huang S. HOTTIP lncRNA Promotes Hematopoietic Stem Cell Self-Renewal Leading to AML-like Disease in Mice. Cancer Cell 2019;36:645-659.e8. [PMID: 31786140 DOI: 10.1016/j.ccell.2019.10.011] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 11.3] [Reference Citation Analysis]
37 Batista CR, Lim M, Laramée AS, Abu-Sardanah F, Xu LS, Hossain R, Bell GI, Hess DA, DeKoter RP. Driver mutations in Janus kinases in a mouse model of B-cell leukemia induced by deletion of PU.1 and Spi-B. Blood Adv 2018;2:2798-810. [PMID: 30355579 DOI: 10.1182/bloodadvances.2018019950] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
38 Viny AD, Bowman RL, Liu Y, Lavallée VP, Eisman SE, Xiao W, Durham BH, Navitski A, Park J, Braunstein S, Alija B, Karzai A, Csete IS, Witkin M, Azizi E, Baslan T, Ott CJ, Pe'er D, Dekker J, Koche R, Levine RL. Cohesin Members Stag1 and Stag2 Display Distinct Roles in Chromatin Accessibility and Topological Control of HSC Self-Renewal and Differentiation. Cell Stem Cell 2019;25:682-696.e8. [PMID: 31495782 DOI: 10.1016/j.stem.2019.08.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 14.3] [Reference Citation Analysis]
39 Bell CC, Fennell KA, Chan YC, Rambow F, Yeung MM, Vassiliadis D, Lara L, Yeh P, Martelotto LG, Rogiers A, Kremer BE, Barbash O, Mohammad HP, Johanson TM, Burr ML, Dhar A, Karpinich N, Tian L, Tyler DS, MacPherson L, Shi J, Pinnawala N, Yew Fong C, Papenfuss AT, Grimmond SM, Dawson SJ, Allan RS, Kruger RG, Vakoc CR, Goode DL, Naik SH, Gilan O, Lam EYN, Marine JC, Prinjha RK, Dawson MA. Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia. Nat Commun 2019;10:2723. [PMID: 31222014 DOI: 10.1038/s41467-019-10652-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 49] [Article Influence: 18.7] [Reference Citation Analysis]
40 Adelman ER, Huang HT, Roisman A, Olsson A, Colaprico A, Qin T, Lindsley RC, Bejar R, Salomonis N, Grimes HL, Figueroa ME. Aging Human Hematopoietic Stem Cells Manifest Profound Epigenetic Reprogramming of Enhancers That May Predispose to Leukemia. Cancer Discov 2019;9:1080-101. [PMID: 31085557 DOI: 10.1158/2159-8290.CD-18-1474] [Cited by in Crossref: 55] [Cited by in F6Publishing: 30] [Article Influence: 18.3] [Reference Citation Analysis]
41 Mattes K, Geugien M, Korthuis PM, Brouwers-Vos AZ, Fehrmann RSN, Todorova TI, Steidl U, Vellenga E, Schepers H. Transcriptional regulators CITED2 and PU.1 cooperate in maintaining hematopoietic stem cells. Exp Hematol. 2019;73:38-49.e7. [PMID: 30986495 DOI: 10.1016/j.exphem.2019.03.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
42 Rhee J, Solomon LA, DeKoter RP. A role for ATP Citrate Lyase in cell cycle regulation during myeloid differentiation. Blood Cells Mol Dis 2019;76:82-90. [PMID: 30853332 DOI: 10.1016/j.bcmd.2019.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
43 Chen J, Kao YR, Sun D, Todorova TI, Reynolds D, Narayanagari SR, Montagna C, Will B, Verma A, Steidl U. Myelodysplastic syndrome progression to acute myeloid leukemia at the stem cell level. Nat Med 2019;25:103-10. [PMID: 30510255 DOI: 10.1038/s41591-018-0267-4] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 20.5] [Reference Citation Analysis]
44 Velcheti V, Schrump D, Saunthararajah Y. Ultimate Precision: Targeting Cancer but Not Normal Self-replication. Am Soc Clin Oncol Educ Book 2018;38:950-63. [PMID: 30231326 DOI: 10.1200/EDBK_199753] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
45 Schuetzmann D, Walter C, van Riel B, Kruse S, König T, Erdmann T, Tönges A, Bindels E, Weilemann A, Gebhard C, Wethmar K, Perrod C, Minderjahn J, Rehli M, Delwel R, Lenz G, Gröschel S, Dugas M, Rosenbauer F. Temporal autoregulation during human PU.1 locus SubTAD formation. Blood 2018;132:2643-55. [PMID: 30315124 DOI: 10.1182/blood-2018-02-834721] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
46 Nakamura M, Wu L, Griffin JD, Kojika S, Goi K, Inukai T, Sugita K. Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk Res 2018;72:34-44. [PMID: 30086426 DOI: 10.1016/j.leukres.2018.07.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
47 Gu X, Ebrahem Q, Mahfouz RZ, Hasipek M, Enane F, Radivoyevitch T, Rapin N, Przychodzen B, Hu Z, Balusu R, Cotta CV, Wald D, Argueta C, Landesman Y, Martelli MP, Falini B, Carraway H, Porse BT, Maciejewski J, Jha BK, Saunthararajah Y. Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 2018;128:4260-79. [PMID: 30015632 DOI: 10.1172/JCI97117] [Cited by in Crossref: 51] [Cited by in F6Publishing: 27] [Article Influence: 12.8] [Reference Citation Analysis]
48 Lambert M, Jambon S, Depauw S, David-Cordonnier MH. Targeting Transcription Factors for Cancer Treatment. Molecules 2018;23:E1479. [PMID: 29921764 DOI: 10.3390/molecules23061479] [Cited by in Crossref: 110] [Cited by in F6Publishing: 89] [Article Influence: 27.5] [Reference Citation Analysis]
49 Melo-Cardenas J, Xu Y, Wei J, Tan C, Kong S, Gao B, Montauti E, Kirsammer G, Licht JD, Yu J, Ji P, Crispino JD, Fang D. USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism. Blood. 2018;132:423-434. [PMID: 29844011 DOI: 10.1182/blood-2017-10-811760] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
50 Pulikkan JA, Castilla LH. Preleukemia and Leukemia-Initiating Cell Activity in inv(16) Acute Myeloid Leukemia. Front Oncol 2018;8:129. [PMID: 29755956 DOI: 10.3389/fonc.2018.00129] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
51 Kim HS, Tan Y, Ma W, Merkurjev D, Destici E, Ma Q, Suter T, Ohgi K, Friedman M, Skowronska-Krawczyk D, Rosenfeld MG. Pluripotency factors functionally premark cell-type-restricted enhancers in ES cells. Nature 2018;556:510-4. [PMID: 29670286 DOI: 10.1038/s41586-018-0048-8] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 7.8] [Reference Citation Analysis]
52 Nagase R, Inoue D, Pastore A, Fujino T, Hou HA, Yamasaki N, Goyama S, Saika M, Kanai A, Sera Y, Horikawa S, Ota Y, Asada S, Hayashi Y, Kawabata KC, Takeda R, Tien HF, Honda H, Abdel-Wahab O, Kitamura T. Expression of mutant Asxl1 perturbs hematopoiesis and promotes susceptibility to leukemic transformation. J Exp Med 2018;215:1729-47. [PMID: 29643185 DOI: 10.1084/jem.20171151] [Cited by in Crossref: 63] [Cited by in F6Publishing: 61] [Article Influence: 15.8] [Reference Citation Analysis]
53 An N, Khan S, Imgruet MK, Gurbuxani SK, Konecki SN, Burgess MR, McNerney ME. Gene dosage effect of CUX1 in a murine model disrupts HSC homeostasis and controls the severity and mortality of MDS. Blood 2018;131:2682-97. [PMID: 29592892 DOI: 10.1182/blood-2017-10-810028] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
54 Cusan M, Cai SF, Mohammad HP, Krivtsov A, Chramiec A, Loizou E, Witkin MD, Smitheman KN, Tenen DG, Ye M, Will B, Steidl U, Kruger RG, Levine RL, Rienhoff HY Jr, Koche RP, Armstrong SA. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML. Blood 2018;131:1730-42. [PMID: 29453291 DOI: 10.1182/blood-2017-09-807024] [Cited by in Crossref: 54] [Cited by in F6Publishing: 45] [Article Influence: 13.5] [Reference Citation Analysis]
55 Freire PR, Conneely OM. NR4A1 and NR4A3 restrict HSC proliferation via reciprocal regulation of C/EBPα and inflammatory signaling. Blood 2018;131:1081-93. [PMID: 29343483 DOI: 10.1182/blood-2017-07-795757] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 6.8] [Reference Citation Analysis]
56 Ji MM, Huang YH, Huang JY, Wang ZF, Fu D, Liu H, Liu F, Leboeuf C, Wang L, Ye J, Lu YM, Janin A, Cheng S, Zhao WL. Histone modifier gene mutations in peripheral T-cell lymphoma not otherwise specified. Haematologica. 2018;103:679-687. [PMID: 29305415 DOI: 10.3324/haematol.2017.182444] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
57 Weng H, Huang H, Wu H, Qin X, Zhao BS, Dong L, Shi H, Skibbe J, Shen C, Hu C, Sheng Y, Wang Y, Wunderlich M, Zhang B, Dore LC, Su R, Deng X, Ferchen K, Li C, Sun M, Lu Z, Jiang X, Marcucci G, Mulloy JC, Yang J, Qian Z, Wei M, He C, Chen J. METTL14 Inhibits Hematopoietic Stem/Progenitor Differentiation and Promotes Leukemogenesis via mRNA m6A Modification. Cell Stem Cell 2018;22:191-205.e9. [PMID: 29290617 DOI: 10.1016/j.stem.2017.11.016] [Cited by in Crossref: 320] [Cited by in F6Publishing: 339] [Article Influence: 64.0] [Reference Citation Analysis]
58 Corces MR, Chang HY, Majeti R. Preleukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia. Front Oncol. 2017;7:263. [PMID: 29164062 DOI: 10.3389/fonc.2017.00263] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
59 Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U. Pharmacological inhibition of the transcription factor PU.1 in leukemia. J Clin Invest 2017;127:4297-313. [PMID: 29083320 DOI: 10.1172/JCI92504] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 9.2] [Reference Citation Analysis]
60 Lin J, Liu W, Luan T, Yuan L, Jiang W, Cai H, Yuan W, Wang Y, Zhang Q, Wang L. High expression of PU.1 is associated with Her-2 and shorter survival in patients with breast cancer. Oncol Lett 2017;14:8220-6. [PMID: 29344265 DOI: 10.3892/ol.2017.7204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
61 Delestré L, Cui H, Esposito M, Quiveron C, Mylonas E, Penard-Lacronique V, Bischof O, Guillouf C. Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells. Haematologica 2017;102:1850-60. [PMID: 28912174 DOI: 10.3324/haematol.2016.157636] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
62 Carvajal LA, Steidl U. Eliminating Cancer Stem Cells in CML with Combination Transcriptional Therapy. Cell Stem Cell 2016;19:6-8. [PMID: 27392220 DOI: 10.1016/j.stem.2016.06.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
63 Ferreira-Teixeira M, Will B. Leukemic Stem Cells S(p)liced Off. Cell Stem Cell 2016;19:561-3. [PMID: 27814474 DOI: 10.1016/j.stem.2016.10.016] [Reference Citation Analysis]
64 Mohr S, Doebele C, Comoglio F, Berg T, Beck J, Bohnenberger H, Alexe G, Corso J, Ströbel P, Wachter A, Beissbarth T, Schnütgen F, Cremer A, Haetscher N, Göllner S, Rouhi A, Palmqvist L, Rieger MA, Schroeder T, Bönig H, Müller-Tidow C, Kuchenbauer F, Schütz E, Green AR, Urlaub H, Stegmaier K, Humphries RK, Serve H, Oellerich T. Hoxa9 and Meis1 Cooperatively Induce Addiction to Syk Signaling by Suppressing miR-146a in Acute Myeloid Leukemia. Cancer Cell 2017;31:549-562.e11. [PMID: 28399410 DOI: 10.1016/j.ccell.2017.03.001] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
65 Jian W, Yan B, Huang S, Qiu Y. Histone deacetylase 1 activates PU.1 gene transcription through regulating TAF9 deacetylation and transcription factor IID assembly. FASEB J 2017;31:4104-16. [PMID: 28572446 DOI: 10.1096/fj.201700022R] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
66 Goto H, Kariya R, Kudo E, Okuno Y, Ueda K, Katano H, Okada S. Restoring PU.1 induces apoptosis and modulates viral transactivation via interferon-stimulated genes in primary effusion lymphoma. Oncogene 2017;36:5252-62. [PMID: 28481873 DOI: 10.1038/onc.2017.138] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
67 Solomon LA, Podder S, He J, Jackson-Chornenki NL, Gibson K, Ziliotto RG, Rhee J, DeKoter RP. Coordination of Myeloid Differentiation with Reduced Cell Cycle Progression by PU.1 Induction of MicroRNAs Targeting Cell Cycle Regulators and Lipid Anabolism. Mol Cell Biol 2017;37:e00013-17. [PMID: 28223367 DOI: 10.1128/MCB.00013-17] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
68 Siwaponanan P, Siegers JY, Ghazali R, Ng T, McColl B, Ng GZ, Sutton P, Wang N, Ooi I, Thiengtavor C, Fucharoen S, Chaichompoo P, Svasti S, Wijburg O, Vadolas J. Reduced PU.1 expression underlies aberrant neutrophil maturation and function in β-thalassemia mice and patients. Blood 2017;129:3087-99. [PMID: 28325862 DOI: 10.1182/blood-2016-07-730135] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
69 Hackl H, Astanina K, Wieser R. Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia. J Hematol Oncol. 2017;10:51. [PMID: 28219393 DOI: 10.1186/s13045-017-0416-0] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 9.6] [Reference Citation Analysis]
70 Shastri A, Will B, Steidl U, Verma A. Stem and progenitor cell alterations in myelodysplastic syndromes. Blood 2017;129:1586-94. [PMID: 28159737 DOI: 10.1182/blood-2016-10-696062] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 9.2] [Reference Citation Analysis]
71 Trompouki E, Flores-Figueroa E, Lucas D, Bowman TV. From the bedside to the bench: new discoveries on blood cell fate and function. Exp Hematol 2017;47:24-30. [PMID: 27931853 DOI: 10.1016/j.exphem.2016.11.007] [Reference Citation Analysis]
72 Yu M, Al-Dallal S, Al-Haj L, Panjwani S, McCartney AS, Edwards SM, Manjunath P, Walker C, Awgulewitsch A, Hentges KE. Transcriptional regulation of the proto-oncogene Zfp521 by SPI1 (PU.1) and HOXC13. Genesis 2016;54:519-33. [PMID: 27506447 DOI: 10.1002/dvg.22963] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
73 Sato H, Wheat JC, Steidl U, Ito K. DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders. Front Oncol 2016;6:187. [PMID: 27597933 DOI: 10.3389/fonc.2016.00187] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
74 Sheng Y, Ju W, Huang Y, Li J, Ozer H, Qiao X, Qian Z. Activation of wnt/β-catenin signaling blocks monocyte-macrophage differentiation through antagonizing PU.1-targeted gene transcription. Leukemia 2016;30:2106-9. [PMID: 27211263 DOI: 10.1038/leu.2016.146] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
75 Botezatu L, Michel LC, Helness A, Vadnais C, Makishima H, Hönes JM, Robert F, Vassen L, Thivakaran A, Al-Matary Y, Lams RF, Schütte J, Giebel B, Görgens A, Heuser M, Medyouf H, Maciejewski J, Dührsen U, Möröy T, Khandanpour C. Epigenetic therapy as a novel approach for GFI136N-associated murine/human AML. Exp Hematol 2016;44:713-726.e14. [PMID: 27216773 DOI: 10.1016/j.exphem.2016.05.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
76 Benetatos L, Vartholomatos G. On the potential role of DNMT1 in acute myeloid leukemia and myelodysplastic syndromes: not another mutated epigenetic driver. Ann Hematol. 2016;95:1571-1582. [PMID: 26983918 DOI: 10.1007/s00277-016-2636-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
77 Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U. New IDH1 mutant inhibitors for treatment of acute myeloid leukemia. Nat Chem Biol 2015;11:878-86. [PMID: 26436839 DOI: 10.1038/nchembio.1930] [Cited by in Crossref: 104] [Cited by in F6Publishing: 93] [Article Influence: 14.9] [Reference Citation Analysis]
78 Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, Trounson A, Turner D, Yamanaka S, Wilmut I. Toward the development of a global induced pluripotent stem cell library. Cell Stem Cell. 2013;13:382-384. [PMID: 24094319 DOI: 10.1016/j.stem.2016.08.003] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 7.0] [Reference Citation Analysis]